Bioretec Ltd's Half-year report 2025: Strong support for future growth from a successful rights issue

Contributed by: PR Newswire

Tags

Bioretec-Report-2025

More Like This

Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results

Bioretec Ltd´s business review Q1 2025: Strong net sales in the first quarter; CE approval with comprehensive indications received in January accelerates the future expansion of RemeOs products

Bioretec Ltd's financial statements bulletin 2023: Another successful year in the growth trajectory

Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025

Bioretec Ltd's business review January-March 2024: Controlled launch in the U.S. progresses

Bioretec Ltd's Annual Report 2024 published

Bioretec Ltd's Annual Report and Financial Statements 2023 published

Bioretec Ltd's Financial Statements 2024 published